Yervoy-Nivolumab Combination Treatment Shrinks Tumors 80 Percent in Three Months
Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint
Trial Shows Standard-Dose Radiotherapy Safer, More Effective than Higher Doses
Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial
Cediranib Demonstates Control In Alveolar Soft Part Sarcoma
Antibody Targeting PD-L1 Shows Fast Tumor Shrinkage
Shared Decisionmaking Called For In PSA Screening For Ages 55-69
ACCP Publishes Guidelines Recommending Low-Dose CT
Study: Routine CT Not Needed In Detecting DLBCL Remissions
Surveillance Following Surgery Sufficient in Stage I Seminoma
Fitness Reduces Risk of Death From Lung, Colorectal, Prostate Cancer in Middle-Aged Men
NCI CTEP Approved Trials For the Month of May
FDA Approves Bayer’s Xofigo For Late-Stage Prostate Cancer
Trending Stories
- On Day 2 as director of NYU Perlmutter, Anirban Maitra talks about the advantages of running a matrix cancer center
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors - Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore
- After a brief government shutdown, FY26 funding bill is signed into law
NIH gets $415M raise, NCI gets $128M more, CDMRP funding largely restored
